These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9542120)

  • 1. High-performance liquid chromatography methods for the separation and quantitation of spironolactone and its degradation products in aqueous formulations and of its metabolites in rat serum.
    Kaukonen AM; Vuorela P; Vuorela H; Mannermaa JP
    J Chromatogr A; 1998 Feb; 797(1-2):271-81. PubMed ID: 9542120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats.
    Kaukonen AM; Lennernäs H; Mannermaa JP
    J Pharm Pharmacol; 1998 Jun; 50(6):611-9. PubMed ID: 9680070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
    Sandall JM; Millership JS; Collier PS; McElnay JC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
    Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
    J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the serum concentration of spironolactone and its metabolites by high-performance liquid chromatography.
    Overdiek JW; Hermens WA; Merkus FW
    J Chromatogr; 1985 Jun; 341(2):279-85. PubMed ID: 4030980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the pharmacokinetics of spironolactone.
    Overdiek HW; Hermens WA; Merkus FW
    Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human adrenal gland as a drug metabolizer: First in-vivo evidence for the conversion of steroidal drugs.
    Hartmann MF; Reincke M; Wudy SA; Bernhardt R
    J Steroid Biochem Mol Biol; 2019 Nov; 194():105438. PubMed ID: 31362063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal Enhancement in the HPLC-ESI-MS/MS analysis of spironolactone and its metabolites using HFIP and NH
    Takkis K; Aro R; Kõrgvee LT; Varendi H; Lass J; Herodes K; Kipper K
    Anal Bioanal Chem; 2017 May; 409(12):3145-3151. PubMed ID: 28224249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites.
    Sungaila I; Bartle WR; Walker SE; DeAngelis C; Uetrecht J; Pappas C; Vidins E
    Gastroenterology; 1992 May; 102(5):1680-5. PubMed ID: 1568578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
    Steimer W; Müller C; Eber B
    Clin Chem; 2002 Mar; 48(3):507-16. PubMed ID: 11861441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous determination of spironolactone and its metabolites in human plasma.
    Jankowski A; Skorek-Jankowska A; Lamparczyk H
    J Pharm Biomed Anal; 1996 Jun; 14(8-10):1359-65. PubMed ID: 8818057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
    Abosehmah-Albidy AZ; York P; Wong V; Losowsky MS; Chrystyn H
    Br J Clin Pharmacol; 1997 Jul; 44(1):35-9. PubMed ID: 9241094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolism and biopharmaceutics of spironolactone in man.
    Overdiek HW; Merkus FW
    Rev Drug Metab Drug Interact; 1987; 5(4):273-302. PubMed ID: 3333882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of HPTLC and green HPLC methods for determination of furosemide, spironolactone and canrenone, in pure forms, tablets and spiked human plasma.
    Naguib IA; Abdelaleem EA; Emam AA; Ali NW; Abdallah FF
    Biomed Chromatogr; 2018 Oct; 32(10):e4304. PubMed ID: 29855049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS.
    Dong H; Xu F; Zhang Z; Tian Y; Chen Y
    J Mass Spectrom; 2006 Apr; 41(4):477-86. PubMed ID: 16541392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.
    Langguth P; Hanafy A; Frenzel D; Grenier P; Nhamias A; Ohlig T; Vergnault G; Spahn-Langguth H
    Drug Dev Ind Pharm; 2005 Mar; 31(3):319-29. PubMed ID: 15830727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples.
    Sora DI; Udrescu S; Albu F; David V; Medvedovici A
    J Pharm Biomed Anal; 2010 Sep; 52(5):734-40. PubMed ID: 20307949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.